1. At a Glance – The Curious Case of a 1938 Dinosaur That Forgot How to Run
Albert David Ltd is like that old Kolkata uncle who owns prime property, has a rich legacy, knows everyone in the industry… but somehow still complains about cash flow every Diwali.
On paper, this company looks like a solid, old-school pharmaceutical player. Founded in 1938, exporting to 35+ countries, WHO supplier, patented placenta-based drug (yes, placenta… we’ll come to that), strong distribution network, low debt, promoter holding above 62%.
And just when you think it can’t get worse — FY25 profits crashed from ₹75 crore to ₹17 crore. That’s not a decline. That’s a financial faceplant.
Even the credit rating agency politely said: “Outlook: Negative” — which in corporate language means, “We’re not panicking yet… but we’re definitely watching.”
And if numbers weren’t enough, management exits started happening like contestants getting eliminated in Bigg Boss.
So the real question is:
Is this a turnaround story… or just a very slow-motion decline disguised as legacy?
2. Introduction – From Pharma Royalty to Margin Misery
Albert David is part of the Kothari Group — a diversified conglomerate with interests in tea, chemicals, textiles, and more.
Historically, this company was a respectable pharmaceutical player with niche strengths:
Placenta-based formulations (Placentrex)
IV fluids manufacturing
Strong export footprint
WHO supply contracts
But somewhere along the journey, growth decided to ghost them.
Let’s talk FY25:
Revenue dropped to ₹345.77 crore (down ~5%)
EBITDA margin collapsed from 13.12% → 1.17%
PAT crashed from ₹75 crore → ₹17 crore
That’s not just a bad year — that’s a full operational breakdown.
Management says this happened because they spent more on marketing and expansion.
Translation:
“We spent money hoping for growth… but growth didn’t show up.”
Classic.
And then comes the cherry on top — multiple resignations:
MD & CEO resigned in Dec 2025
Another senior leader resigned in March 2026
So now you have:
Falling margins
Declining profits
Leadership exits
Tell me honestly — would you trust your pharmacy prescription to this level of instability?
3. Business Model – WTF Do They Even Do?
Let’s simplify this like explaining to your cousin who just opened a Demat account after watching Instagram reels.
Albert David does three main things:
1. Pharma Formulations
Tablets, capsules, syrups, ointments
IV fluids (glass + plastic bottles)
Ophthalmic products
2. Specialty Product – Placentrex
A placenta-based drug
Contributes ~20–21% of revenue
Market leader in India
Patent-protected
Yes, this is their superstar product.
But also… their biggest risk.
Because when one product contributes so much, you’re basically saying:
“If this fails, we’re in trouble.”
3. Export Business
95% of revenue comes from exports
Markets: Africa, Southeast Asia, Latin America
That sounds impressive.
But here’s the twist:
Exports are declining, which increases forex risk because imports are still happening.
So now you have:
Export dependency
Falling exports
Currency risk
That’s like trying to ride a bike while the wheels are slowly deflating.
4. Financials Overview – Numbers That Need Therapy
(All figures in ₹ crore)
Metric
Latest Quarter (Dec 2025)
YoY (Dec 2024)
QoQ (Sep 2025)
YoY %
QoQ %
Revenue
90
83
87
+8.4%
+3.4%
EBITDA
11
1
3
Massive jump
+267%
PAT
15
-9
-3
Turnaround
Strong
EPS
26.81
-16.45
-5.78
Turnaround
Strong
Now before you celebrate…
This “great quarter” is after multiple bad quarters.
